News

MEDI8897, which is a single dose extended half-life anti-RSV F monoclonal antibody (mAb), is being developed jointly by AstraZeneca’s biologics research and development arm MedImmune and Sanofi Pasteur.

The approval being sought from the US Food and Drug Administration (FDA) is for the post-surgery use of Kadcyla in patients with HER2-positive early breast cancer with residual

Data were presented at the Sleep Research Society’s Advances in Sleep and Circadian Science conference, taking place in Clearwater Beach, Florida, Feb. 1-4, 2019. SUNRISE 2 was a

The early-stage trial will study safety, pharmacokinetics, and pharmacodynamics of VE-1902 in 100-120 participants. The blood thinner is the first PRrecision Oral AntiCoagulant (PROAC) of the US-based pharma

This solutions suite, supported by more than 1,000 dedicated employees, will deliver simplified operating procedures, specialized teams, and services to provide a more agile way for these innovators

The CHMP’s positive opinion for Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel is for the first-line treatment of metastatic NSCLC in adults. Keytruda is an

Newron expects to report top line results from the STARS study in Q4 2019. Rett syndrome, a severe neuro-developmental orphan disease with no approved treatment options, overwhelmingly affects

The CHMP’s positive opinion for the marketing authorization of Forxiga is for use as an oral adjunct treatment to insulin in adults with T1D. Forxiga, which is a

Farmax, located in Hradec Králové, Czech Republic, was the commercial division of SVUS Pharma, and has a strong distribution presence in the Czech Republic, Slovakia as well as